As CEO of Animab, Alain is committed to developing cutting-edge biotechnology for better animal performance. With over twenty years’ experience in animal health in roles at Merial and Boehringer Ingelheim, Allain has a wealth of industry knowledge which he applies to Animab’s development of orally administered antibodies, designed to improve the performance of livestock animals.